

October 24, 2018



## **Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference**

**-Actinium executives will showcase multiple partnering opportunities available via pipeline candidates and technology platform**

**-Assets available for partnering include highly differentiated targeted conditioning Antibody Radio-Conjugates including Pivotal Phase 3 Program lomab-B, CD33 Actimab program including Actimab-MDS, Antibody Warhead Enabling technology platform and the lomab-ACT program next generation lymphodepletion technology for use prior to CAR-T**

NEW YORK, Oct. 24, 2018 /PRNewswire/ --**Actinium Pharmaceuticals, Inc.** (NYSE American: ATNM) announced today that members of the Company's executive team will attend the BIO-Europe® 24th Annual International Partnering Conference in Copenhagen, Denmark on November 5-7, 2018. BIO-Europe® is the largest life science partnering event in Europe that is expected to draw over 4,000 attendees from over 2,000 companies.



Actinium is developing Antibody Radio-Conjugates (ARCs) that deliver radioisotopes in a targeted manner to cells expressing CD45 and CD33 for multiple hematologic indications. Actinium is the only company with multi-disease, multi-target pipeline focused on improving access and outcomes to cellular therapies including bone marrow transplant and CAR-T through targeted conditioning. Actinium's lead targeted conditioning product candidate, lomab-B, is currently being studied in a pivotal Phase 3 trial. Actinium's best-in-class CD33 program is being studied in multiple trials as both a targeted conditioning agent and therapeutic for patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome and Multiple Myeloma. Underpinning Actinium's clinical programs is its Antibody Warhead Enabling technology that has been studied in both hematologic and solid tumors, which could be utilized to create ARCs for numerous targets and indications.

Sandesh Seth, Actinium's Chairman and Chief Executive Officer said, "We are particularly excited for this year's BIO-Europe Partnering Conference for a multitude of reasons. Given the progress and expansion of our targeted conditioning pipeline combined with the strong interest for radiopharmaceutical therapies of late, we look forward to what we expect to be a productive and valuable conference. First and foremost, we will be able to highlight extensive clinical data from our highly differentiated CD45 and CD33 ARCs for targeted conditioning and therapeutic indications, which have been studied in over 600 patients across 14 clinical trials. We will also showcase our recently unveiled lomab-ACT program that we intend to make a universally available next generation lymphodepletion solution prior to CAR-T therapy. Additionally, we will present our AWE technology platform to potential collaborators and partners just as we have with our established AWE collaborator Astellas Pharma, Inc."

Conference attendees may schedule a meeting with Actinium's management through the conference's partnering system <https://ebdgroup.knect365.com/bioeurope/login> or by contacting Steve O'Loughlin, Actinium's Principal Financial Officer, [soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com).

### **About BIO-Europe**

The 24th annual BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO)

### **About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals Inc. is focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free or sparing, targeted conditioning technology. Actinium is the only company with a multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by ARC's or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium's pipeline of clinical-stage targeted conditioning ARCs target the antigens CD45 and CD33 for patients with a broad range of hematologic malignancies including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM), Acute Lymphoblastic Leukemia (ALL), Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. Actinium's lomab-ACT program is designed to be a universal lymphodepletion technology intended to eliminate the need for chemotherapy-based conditioning prior to CAR-T or other adoptive cellular therapies.

lomab-B, Actinium's lead targeted conditioning product candidate, is currently enrolling patients in the pivotal Phase 3 SIERRA trial in patients age 55 or older, with active, relapsed or refractory AML. Iodine-131-apamistamab (lomab-B), combines the anti-CD45 monoclonal antibody labeled with iodine-131 for myeloablation prior to a bone marrow transplant. CD45 is expressed on leukemia, lymphoma and normal immune cells. lomab-B has been studied in over 500 patients in 10 clinical trials in numerous hematologic diseases. Actinium's lomab-

ACT program is an expansion of its CD45 program that is intended to be a universal, chemotherapy-free solution for targeted lymphodepletion prior to CAR-T. Through targeted lymphodepletion, the lomab-ACT program is expected to improve CAR-T cell expansion, reduce CAR-T related toxicities and expand patient access to CAR-T treatment and potentially other adoptive cell therapies. Due to its lower payload dose, lymphodepletion with the lomab-ACT program can be accomplished through a single outpatient infusion. Actinium intends to advance its lomab-ACT program with CAR-T focused collaborators from academia and industry.

Actinium's pipeline also includes a potentially best-in-class CD33 program with its ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in multiple Phase 2 and Phase 1 clinical trials for targeting conditioning and as a therapeutic in multiple diseases and indications including AML, MDS and MM. Actinium applies its CD33 program at high doses to target CD33+ cells of the myeloid lineage in combination with reduced intensity conditioning (RIC), which together are intended to result in myeloablative outcomes with a more benign and well tolerated profile than high intensity chemotherapy myeloablation. Actinium is focused on applying its CD33 program at low doses in combination with other therapeutic modalities including chemotherapy, targeted agents and immunotherapies.

Actinium is also developing its proprietary AWE or Antibody Warhead Enabling technology platform which utilizes radioisotopes including iodine-131 and the highly differentiated actinium-225 coupled with antibodies to target a variety of antigens that are expressed in hematological and solid tumor cancers. The AWE technology enables Actinium's internal pipeline and with the radioisotope Actinium-225 is being utilized in a collaborative research partnership with Astellas Pharma, Inc. Actinium's clinical programs and AWE technology platform are covered by a portfolio of 77 patents covering composition of matter, formulations, methods of use and also methods of manufacturing the radioisotope Actinium-225 in a cyclotron.

More information is available at [www.actiniumpharma.com](http://www.actiniumpharma.com) and our Twitter feed @ActiniumPharma, [www.twitter.com/actiniumpharma](https://www.twitter.com/actiniumpharma).

### **Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

**Contact:****Actinium Pharmaceuticals, Inc.**

Steve O'Loughlin

Principal Financial Officer

[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

**Investor Relations**

Rx Communications Group

Paula Schwartz

917-322-2216

[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

 View original content to download multimedia <http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-participation-at-bio-europe-24th-annual-international-partnering-conference-300736713.html>

SOURCE Actinium Pharmaceuticals, Inc.